Navigation Links
Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor Ian Meredith, M.D., Monash Medical Centre, Melbourne, Australia, on Tuesday presented positive nine-month results from the Medtronic RESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain, with data showing a low number of adverse cardiac events and no protocol-defined stent thrombosis. The next-generation Medtronic (NYSE:MDT) Endeavor(R) Resolute drug-eluting stent system with new BioLinx(TM) polymer is designed to address the special needs of patients who have complex medical conditions and is engineered to match the duration of drug delivery with the longer healing duration often required by these patients.

In clinical results at nine months, the Endeavor RESOLUTE trial showed no Target Lesion Revascularization (TLR), no Target Vessel Revascularization (TVR) and a Major Adverse Cardiac Event (MACE) rate of just 7.0%. Of the trial's 130 patients, 129 (99.2%) received clinical follow-up, and 95 had angiographic follow-up. In-stent late lumen loss, the study's primary endpoint, was 0.22 mm, while in-segment late loss was 0.12 mm. In-stent Angiographic Binary Restenosis (ABR) was 1.0% percent and in-segment ABR was 2.1%.

"What is most impressive about these results is that they occurred in a patient population with complex and challenging characteristics," said Dr. Meredith, the principal investigator of the trial, noting that the average lesion length in the RESOLUTE trial was 15.5 mm and nearly 82% of enrolled patients were classified as having challenging B2/C lesions. "The RESOLUTE trial enrolled a high percentage of patients with lesions that are difficult to treat, including small vessels and long lesions, and these results are extremely promising. Zotarolimus continues to be a very potent drug in preventing restenosis while the new BioLinx polymer appears to be delivering the drug as intended."

Endeavor Resolute leverage
'"/>




Page: 1 2 3

Related medicine technology :

1. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
2. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
3. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:11/21/2014)... 20, 2014   Wellcentive , the industry ... healthcare organizations, announced today being named one of ... Innovation Award .  Sponsored by Intel, the world ... fourth year, recognizes companies developing leading-edge technology and ... processes. Wellcentive,s Mason Beard ...
(Date:11/18/2014)... , Nov. 18, 2014  Sanguine Biosciences – ... engagement and study recruitment – will use its ... to help Pfizer Inc. find and recruit people ... their family members to participate in voluntary research, ... DNA mutations and hopefully aid in informing the ...
(Date:11/18/2014)... -- BioLink 2015, the BioPh & ICSE BioPharm ... CCCMHPIE ( China Chamber of Commerce for ... UBM Live and Beijing Yizhuang Biomedical Park, will ... Yizhuang Biomedical Park.   ... will gather 200+ decision makers from biopharmaceutical industrial players ...
Breaking Medicine Technology:Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2BioLink 2015 Will be Held on Jan 22, 2015, with a Focus on Biopharma Industrial Innovation & International Technology Transfer 2BioLink 2015 Will be Held on Jan 22, 2015, with a Focus on Biopharma Industrial Innovation & International Technology Transfer 3
... Fla., Dec. 29 Connectyx Technologies Holdings Group, Inc. (Other ... RV Owners Community as a marketing partner to its MedFlash ... million members and more than 3,400 individual club chapters and ... Club provides its membership with essential services ranging from towing ...
... , REDWOOD CITY, Calif., Dec. 28 Codexis, Inc. announced today ... the U.S. Securities and Exchange Commission ("SEC") relating to the proposed ... shares of common stock to be sold in this offering are ... stockholders. , Credit Suisse Securities (USA) LLC and Goldman, Sachs & ...
Cached Medicine Technology:Connectyx Announces MedFlash Sales Partnership with National Recreational Vehicle Club 2Connectyx Announces MedFlash Sales Partnership with National Recreational Vehicle Club 3Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering 2
(Date:11/21/2014)... Nov. 20, 2014 (HealthDay News) -- Some people with ... implant,s internal magnet when they undergo an MRI scan, ... supplied by the researchers, about 300,000 people worldwide have ... to people who are deaf or have severe hearing ... people with cochlear implants when undergoing MRI. One ...
(Date:11/21/2014)... Serena Gordon HealthDay ... Two U.S. government agencies have proposed new rules that ... clinical trial was successful or not. The proposed ... to publish summaries of their results to ClinicalTrials.gov -- a ... Health (NIH) and the U.S. Department of Health and Human ...
(Date:11/21/2014)... They</i> Need a Kidney" style="border-width:0px;" /> THURSDAY, Nov. 20, 2014 ... most selfless acts one person can do for another. And ... they need a kidney later in life are benefiting from ... Living donors provided organs for almost 6,300 of the ... in 2010, according to background information supplied by the study ...
(Date:11/18/2014)... 2014 On November 18, 2014, My ... Tails magazine publisher Keith Simmons for an episode. At ... “You also are the publisher of the Traveler Charleston ... one another?” Simmons responds, “Our company is Traveler Communication ... is Traveler Charleston and then we custom publish a ...
(Date:11/18/2014)... 2014 Examination Management Services, Inc. ... management and investigative services, has launched a proprietary ... to enhance its paramedical exam service to life ... use of EMSI’s 5 Star Examiner Performance Model, ... paramedical exams are conducted by examiners whose performance ...
Breaking Medicine News(10 mins):Health News:MRI Can Be Painful, Disruptive for People With Cochlear Implants 2Health News:U.S. Proposes Greater Public Access to Data From Clinical Trials 2Health News:Study Supports Giving Kidney Donors Priority When They Need a Kidney 2Health News:My Positive Perspective Broadcasts Episode Discussing Animal Rights and Carolina Tails Magazine 2Health News:EMSI Launches Proprietary 5 Star Examiner Performance Model to Enhance Paramedical Exam Service 2
... to particular product brands,when their level of anxiety ... study in the, Journal of Consumer Research . ... Korea,University), James E. Burroughs (University of Virginia), and ... and insecurity,in consumers and discovered that the combination ...
... 2009) There is hope that the drug rasagiline can ... -- slow the progression of a devastating degenerative brain disease ... function. , Now a new study looking at the ... that people who began the drug earlier continued to do ...
... Ariz., Jan. 26 The Providence Service ... Center on Budget and Policy Priorities, preliminary analysis of ... package. The report was issued on January 22, ... is one of the nation,s premier policy organizations working ...
... you can get a more aggressive treatment for facial ... Calif., Jan. 26 The Pearl procedure is used ... skin and aging to provide a healthy, pearl-like glow. ... selected pattern, the laser concurrently sends heat to the ...
... Students across the,country will soon kick off Olive ... Leukemia & Lymphoma Society,s (LLS) School,& Youth campaign. ... ) , A ... and school,administrators, Pasta for Pennies has raised more ...
... CIGNA using incentives to foster healthy choices.LYNDHURST, N.J., ... integrated incentive solutions to the healthcare industry, announced ... has launched a new "points-based" health incentive program ... will offer employers ways to motivate their employees ...
Cached Medicine News:Health News:Security blankets: Materialism and death anxiety lead to brand loyalty 2Health News:Patients starting Parkinson's drug rasagiline earlier do better 2Health News:Providence Service Corporation Provides The Center on Budget and Policy Priorities' Preliminary Analysis of Potential Medicaid Assistance for States in the House Economic Recovery Package 2Health News:Providence Service Corporation Provides The Center on Budget and Policy Priorities' Preliminary Analysis of Potential Medicaid Assistance for States in the House Economic Recovery Package 3Health News:Renaissance Laser & Vein Institute (LaserandVeinclinic.com) 'Pearl Treatment' 2Health News:Olive Garden's Pasta for Pennies Makes Cents for Cancer Research 2Health News:IncentOne Provides Incentive Solution to CIGNA 2
... Celestial Star™ light is ... The flexible design allows ... positioning. The space-saving structure ... facilities including emergency rooms, ...
The Next Generation in Single Lamp Technology, Advanced Optics & Reflector Design, Extended Depth of Field, 54" Useable Column of Light, High Intensity, Cool Beam Temperature...
... its introduction to the market, the U100 ... proven itself as a highly efficient and ... of urology and gastroenterology. The new U100Plus ... technically further developed and improved in many ...
ELVeS™ (Endo Laser Vein System) from biolitec is a versatile, easy to use & complete system that allows you to treat all conditions resulting from venous incompetence. (ELVeS has FDA clearance ...
Medicine Products: